Tubulin beta chain · SINGLE PROTEIN · Giardia intestinalis
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Tubulin beta chain shows clinical signal disease relevance led by Helminthiasis. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P05304. Start with Helminthiasis, then reuse UniProt P05304 as the stable protein anchor across project notes and exports.
Start with Helminthiasis, then reuse UniProt P05304 as the stable protein anchor across project notes and exports.
Tubulin beta chain shows clinical signal disease relevance led by Helminthiasis. 1 linked drug remains visible in the same block.
Start review with Helminthiasis because it currently carries clinical signal support. Linked drugs include FENBENDAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTubulin beta chain
Review this target as Tubulin beta chain, mapped to UniProt P05304. Sequence length is 446 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tubulin beta chain as ChEMBL target CHEMBL5058521, mapped to UniProt P05304. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Tubulin beta chain is the right protein anchor across sources, using UniProt P05304 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Helminthiasis is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Tubulin beta chain |
| Target Type | SINGLE PROTEIN |
| Organism | Giardia intestinalis |
| UniProt | P05304 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Tubulin beta chain |
| UniProt Accession | P05304 |
| Component Type | Protein |
| Sequence Length | 446 aa |
Tubulin beta chain
Review this target as Tubulin beta chain, mapped to UniProt P05304. Sequence length is 446 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Tubulin beta chain shows clinical signal disease relevance led by Helminthiasis.
Start review with Helminthiasis because it currently carries clinical signal support. Linked drugs include FENBENDAZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.